{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:33:01Z","timestamp":1786635181174,"version":"build-2736575974"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare oncological outcomes between intravesical bacillus Calmette\u2010Gu\u00e9rin (BCG) and gemcitabine\/docetaxel (Gem\/Doce) in patients with primary high\u2010grade (HG) Ta non\u2010muscle\u2010invasive bladder cancer (NMIBC) and assess the prognostic utility of the American Urological Association (AUA) risk stratification system, which classifies these tumours as intermediate risk (IR) or high risk (HR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      Retrospective cohort of 128 treatment\u2010na\u00efve patients with HG Ta NMIBC treated from January 2011 to December 2024 was analysed. After resection, patients received intravesical therapy with either BCG (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200965) or Gem\/Doce (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200963), with Gem\/Doce on a 24\u2010month maintenance schedule and BCG at 3, 9, and 15\u2009months. Cox regression models evaluated the impact of patient, disease, and treatment characteristics on oncological outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The follow\u2010up was longer in the BCG group (median [interquartile range, IQR] 81\u2009[44\u2013113]\u2009months) than in the Gem\/Doce group (median [IQR] 37\u2009[26\u201355]\u2009months). Recurrence\u2010free survival (RFS) at 12 and 24\u2009months was 80% and 76% for Gem\/Doce, and 76% and 70% for BCG, respectively. HG\u2010RFS at 12 and 24\u2009months was 82% and 78% for Gem\/Doce, and 79% and 75% for BCG, respectively. The 24\u2010month progression\u2010free survival was 100% for Gem\/Doce and 91% for BCG. There were no significant associations between AUA risk classification (IR vs HR; hazard ratio 1.05,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.89 for RFS; hazard ratio 1.12,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.75 for HG\u2010RFS) or treatment type (BCG vs Gem\/Doce; hazard ratio 1.19,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.60 for RFS; hazard ratio 1.02,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.96 for HG\u2010RFS) and recurrence outcomes. Adverse events were less frequent with Gem\/Doce than BCG (40% vs 46%), with no Grade III events in the Gem\/Doce group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treatment with Gem\/Doce is a well\u2010tolerated, effective alternative to BCG for HG Ta NMIBC. In this subset, AUA risk stratification (IR vs HR) was not significantly associated with recurrence outcomes, warranting prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.70149","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:21:37Z","timestamp":1768821697000},"page":"690-697","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine\/docetaxel in high\u2010grade Ta non\u2010muscle\u2010invasive bladder cancer"],"prefix":"10.1111","volume":"137","author":[{"given":"Mohamad","family":"Abou Chakra","sequence":"first","affiliation":[{"name":"Department of Urology University of Iowa Health Care  Iowa City IA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"McElree","sequence":"additional","affiliation":[{"name":"Department of Urology Vanderbilt University Medical Center  Nashville TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Mott","sequence":"additional","affiliation":[{"name":"Holden Comprehensive Cancer Center University of Iowa  Iowa City IA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7202-6427","authenticated-orcid":false,"given":"Michael A.","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"Department of Urology University of Iowa Health Care  Iowa City IA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.07.027"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003846"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.07.017"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.05.005"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2018.06.018"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.05.045"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2020.10.039"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.02.010"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2310073"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.21037\/tau-2025-661"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1519428"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01651"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-025-05613-5"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.0849"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2005.11.026"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.06.147"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000136446.37840.0a"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2012.03089.x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/23523735251324318"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-04992-5"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000688"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.12.033"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.07.016"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002678"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.05.016"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70149","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bju.70149","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:42:50Z","timestamp":1786632170000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.70149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/bju.70149"],"URL":"https:\/\/doi.org\/10.1111\/bju.70149","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"2026-01-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}